Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

The Diagnosis of Primary Aldosteronism: Testing 2 Screening Approaches in a Large Reference Laboratory Population

ENDO2024

Boston, MA, June 1-4, 2024

Poster presentation: The Diagnosis of Primary Aldosteronism: Testing 2 Screening Approaches in a Large Reference Laboratory Population

Authors: Marcelli M, Bi C, Funder JW, McPhaul MJ

Specialty: Endocrinology, Cardiology, Cardiovascular disease

Related content

Conference Presentation
Positivity Rates of Screening Criteria for Primary Aldosteronism: A Cohort Comparison Study
On-Demand Webinar
How to Close Gaps in Care by Maximizing the Power of Laboratory Stewardship Solutions
On-Demand Webinar
Cardiovascular Clinical Conversations: Inflammatory Markers for Defining Cardiovascular Risk
On-Demand Webinar
Innovative Solutions: LC-MS/MS

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.